Jump to content

IDM-2101 follow up data indicates positive survival trend in


Recommended Posts

Monday, IDM Pharma, Inc. (IDMI: News, Chart, Quote ), a biopharmaceutical company, announced that follow up data from Phase 2 study of IDM-2101 indicated positive survival trend in non-small cell lung cancer, or NSCLC, patients and that the drug candidate was well tolerated.

"We continue to be encouraged by the positive trend in overall survival we are seeing in patients treated with IDM-2101. Based on the results to date, further clinical study is warranted to confirm the potential of IDM-2101 as a treatment option for patients with non-small cell lung cancer," said Minal Barve, practice director, Mary Crowley Cancer Research Center.

According to Irvine, California-based IDM Pharma, the Phase 2 trial was designed to evaluate one-year patient survival, overall survival and vaccine immunogenicity in HLA-A2 positive patients with stage IIIb, IV or recurrent non-small cell lung cancer or NSCLC.

The Phase 2 IDM-2101 study began in late 2004 and patient treatment has been completed. Long-term follow-up on overall survival is ongoing, the company added.

Timothy Walbert, President and CEO, IDM Pharma said that the study results will serve as a basis in determining an appropriate clinical pathway for this important treatment.

IDMI is trading up $0.23 or 11.00% at $2.32 on a volume of 696 thousand shares.

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.